Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: A pooled analysis of four clinical trials

International Journal of COPD

Volumn 9, Issue , 2014, Pages 657-673

  Rennard, Stephen I ^a   Sun, Shawn X ^b   Tourkodimitris, Stavros ^b   Rowe, Paul ^b   Goehring, Udo M ^c   Bredenbröker, Dirk ^c   Calverley, Peter M A ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Takeda Pharmaceuticals International GmbH   (Switzerland)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Breathlessness; Lung function; Phosphodiesterase 4 inhibitor; Subgroup analyses

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SCORING SYSTEM; TRANSITION DYSPNEA INDEX; AGED; COMPLICATION; CONVALESCENCE; DRUG EFFECTS; FEMALE; LUNG; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

AGED; AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903268704     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S55738     Document Type: Article

References (38)

1. Vestbo J, Hurd SS, Agusti AG, etal. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4): 347-365.
2. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999;159(1):321-340.
3. Parshall MB, Schwartzstein RM, Adams L, etal. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4): 435-452.
4. Mahler DA, Weinberg DH, Wells CK, etal. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758.
5. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99-103.
6. Jones PW, Mahler DA, Gale R, etal. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med. 2011;105(6):892-899.
7. Jones PW, Singh D, Bateman ED, etal. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830-836.
8. Kaplan A. Effect of tiotropium on quality of life in COPD: a systematic review. Prim Care Respir J. 2010;19(4):315-325.
9. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580-586.
10. Nannini L, Cates CJ, Lasserson TJ, etal. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4): CD003794.
11. Grootendorst DC, Gauw SA, Verhoosel RM, etal. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081-1087.
12. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2): 180-184.
13. Calverley PM, Rabe KF, Goehring UM, etal. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-694.
14. Calverley PM, Sanchez-Toril F, McIvor A, etal. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154-161.
15. Rennard SI, Calverley PM, Goehring UM, etal. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
16. Cazzola M, MacNee W, Martinez FJ, etal. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
18. Halpin DM, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD. 2009;6(3):211-225.
19. Jones PW, Donohue JF, Nedelman J, etal. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
20. Mahler DA, Ward J, Waterman LA, etal. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136(6):1473-1479.
21. Westwood M, Bourbeau J, Jones PW, etal. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
22. Casaburi R, Mahler DA, Jones PW, etal. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
23. Dahl R, Chung KF, Buhl R, etal. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
24. Kerwin E, Hebert J, Gallagher N, etal. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. 2012;40(5): 1106-1114.
25. Watson L, Schouten JP, Lofdahl CG, etal. Predictors of COPD symptoms: does the sex of the patient matter? Eur Respir J. 2006;28(2): 311-318.
26. Ambrosino N, Foglio K, Balzano G, etal. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis. 2008;3(4):771-780.
27. Forest Research Institute Core Presentation for the April 7, 2010 meeting of the Pulmonary-Allergy Drugs Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM208711.pdf. Accessed April 1, 2013.
28. Rabe KF, Bateman ED, O'Donnell D, etal. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563-571.
29. Rennard SI, Sun SX, Tourkodimitris S, etal. Effect of roflumilast treatment added to tiotropium on dyspnea in patients with chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med. 2012;185:A2261.
30. Eakin EG, Resnikoff PM, Prewitt LM, etal. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest. 1998;113(3):619-624.
31. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, etal. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.
32. Pan L, Guo YZ, Zhang B, etal. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis. 2013;5(4):422-429.
33. Curtis JR, Deyo RA, Hudson LD. Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax. 1994;49(2): 162-170.
34. Hajiro T, Nishimura K, Tsukino M, etal. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest. 1999;116(6):1632-1637.
35. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25-31.
36. Rennard S, Calverley PMA, Sun SX, etal. Effect of roflumilast treatment on health-related quality of life in patients with chronic obstructive pulmonary disease [abstract]. Respir Care. 2011;10:1641.
37. Jenkins CR, Celli B, Anderson JA, etal. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38-45.
38. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6: 493-501.